| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| WB Predicted band size | 65 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human CHDH |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CHDH抗体的3篇参考文献及其简要摘要：
1. **文献名称**：*"Development and Application of a Polyclonal Antibody Against Human Choline Dehydrogenase (CHDH)"*
**作者**：Li Y et al.
**摘要**：本研究报道了一种针对人源胆碱脱氢酶(CHDH)的多克隆抗体的开发，并通过Western blot和免疫荧光验证其特异性，成功应用于检测多种组织及细胞系中CHDH的蛋白表达水平。
2. **文献名称**：*"CHDH Modulates Mitochondrial ROS and Apoptosis via Folate Metabolism"*
**作者**：Wang X et al.
**摘要**：文章利用特异性CHDH抗体探究了CHDH在调控线粒体活性氧(ROS)及细胞凋亡中的作用，揭示其通过叶酸代谢途径影响氧化应激反应的分子机制。
3. **文献名称**：*"Altered CHDH Expression in Alzheimer’s Disease: Insights from Immunohistochemical Analysis"*
**作者**：Chen L et al.
**摘要**：该研究通过CHDH抗体进行脑组织免疫组化分析，发现阿尔茨海默病患者脑区中CHDH表达显著降低，提示其可能参与神经退行性病变的代谢异常过程。
(注：以上文献为示例，实际引用时需核对真实存在的论文信息。)
CHD (choline dehydrogenase) antibodies are immunological tools used to detect and study the CHD enzyme, a mitochondrial protein encoded by the *CHDH* gene. CHD catalyzes the oxidation of choline to betaine aldehyde in the choline degradation pathway, a critical step in synthesizing betaine, which serves as a methyl donor in homocysteine metabolism and epigenetic regulation. This enzyme plays a role in lipid metabolism, energy homeostasis, and cellular stress responses. Dysregulation of CHD has been linked to metabolic disorders, neurodegenerative diseases, and cancer.
CHD antibodies are primarily utilized in research to investigate CHD expression, localization, and function in various tissues and disease models. They enable techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein levels, mitochondrial distribution, or altered activity in pathological conditions. Polyclonal and monoclonal antibodies are available, often validated for specificity in human, mouse, or rat samples. Recent studies also explore CHD's potential as a biomarker for metabolic syndrome or its interaction with other mitochondrial proteins.
However, cross-reactivity or variability in antibody performance across species or experimental conditions requires careful validation. Ongoing research aims to clarify CHD's role in cellular pathways and its therapeutic implications, driving demand for reliable CHD antibodies in both basic and translational studies.
×
